References
- Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother 2000;34:1173–1178.
- Pui CH. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 2007;48:1672–1673.
- Sancho JM, Morgades M, Alonso N, . Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Med Clin (Barc) 2008;131:441–446.
- Garcia-Marco JA, Panizo C, Garcia ES, . Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009;115:1892–1898.
- Glantz MJ, Jaeckle KA, Chamberlain MC, . A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Anticancer Drugs 1999;5:3394–3402.
- Phuphanich S, Maria B, Braeckman R, . A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007;81:201–208.
- Glantz MJ, LaFollette S, Jaeckle KA, . Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110–3116.
- McClune B, Buadi FK, Aslam N, . Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 2007;48:1849–1851.
- Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, . Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol 2011;103:603–609.
- Ostermann K, Pels H, Kowoll A, . Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol 2011;103: 635–640.
- Gökbuget N, Hartog CM, Bassan R, . Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011;96:238–244.